Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

e-cigarettes

- PMLiVE

EU hits Servier and generic firms with €428m ‘pay-for-delay’ fine

Follows deals to delay competition for blood pressure drug Coversyl/Aceon

France flag

Pharma criticises France’s backing for off-label Avastin use

EFPIA weighs in on proposal to move wet AMD patients to the drug as a cheaper alternative

- PMLiVE

Japan first to approve Roche’s lung cancer drug alectinib

Personalised medicine has same target as Pfizer’s Xalkori and Novartis’ Zykadia

- PMLiVE

Roche wins In-House Team of the Year at Communiqué Awards

"Brave and courageous" UK communications team picks up honour

- PMLiVE

France wants Avastin used in place of Lucentis

Government calls for off-label use of Roche drug in order to reduce spend on eye therapy

Roche - Basel

Roche makes $1.7bn oncology acquisition

Takes over Seragon and its pipeline of investigational breast cancer treatments

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

Teva’s chair Philip Frost to step down

He will leave the Israeli pharma company by the end of the year

- PMLiVE

Teva restructures to stengthen unit identities

First major change at Israeli firm since Erez Vigodman’s appointment as CEO

- PMLiVE

Teva to use cloud-based CRM for sales force

Picks Veeva’s system to streamline operations

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links